Supreme Court to Hear Hospital Drug Pricing Case in Medicare Test
The Supreme Court will hear a case on Medicare drug price determination. This is one of many tests of healthcare [...]
ICER Finds Insufficient Clinical Benefit for Controversial Alzheimer’s Drug in Revised Report and Calls for Price Reduction Ahead of CTAF meeting
The Institute for Clinical and Economic Review (ICER) has issued a revised evidence report on Biogen’s Aduhelm, or aducanumab. ICER [...]
CEVR and FDA Experts Discuss Medicare’s Options Regarding Aduhelm Coverage
The Food and Drug Administration recently approved Biogen’s new therapy for use in Alzheimer’s disease, Aduhelm. However, Medicare’s decision to [...]
Webinar on Value-Based Pricing Now Available On-Demand
Authors of a recently released book on drug pricing, The Right Price: A Value-Based Prescription for Drug Costs, hosted a webinar [...]
Cigna’s New Shared Savings Program Offers $500 if Members Convert to Biosimilars as Billion Dollar Savings Loom
Cigna has launched a Shared Savings Program, aimed at reducing costs for its members by identifying alternative drugs offered at [...]
Alzheimer’s Drug Could Equal Federal Government’s Spending on NASA
Biogen’s Aduhelm is exceedingly expensive at $56,000. If covered under Medicare, its cost could approach the federal government’s spending on [...]
Biogen Considers Aduhelm Price Cut as Competing Alzheimer’s Drug Approved by FDA
Biogen and its partner Eisai released a statement regarding Alzheimer’s Drug Aduhelm, which is priced at $56,000 per year. The [...]
Is Prescription Drug Price Negotiation a Lasting Trend?
One proposed solution to high prescription drug prices is negotiating directly with manufacturers. Legislative changes allowing Medicare to carry out [...]
CVS Eliminates 72 Hyperinflated Drugs, Saving $1.2 Billion in 2020
CVS has removed 72 high-priced drugs from its formulary. This move has led to $1.2 billion in savings last year [...]
Five Blue Cross Blue Shield Health Insurance Plans to Incorporate Evio to Cut Costs
Five Blue Cross Blue Shield insurance plans will utilize Evio to reduce healthcare costs, including high prescription drug costs. This [...]
New Report Examines Generic Drug Uptake Trends and Impact on Healthcare Costs
ISPOR’s Value in Health journal recently published an article examining generic drug uptake trends in the United States. Researchers assessed [...]
New ISPOR Article Compares Net Drug Prices and ICER’s Value-Based Prices
A new article, published in ISPOR’s Value in Health journal, assesses drug prices by comparing net prices to the Institute [...]
Biogen Partners with Cigna and CVS Health to Promote Access to Contentious Alzheimer’s Drug
Biogen has announced that it will partner with Cigna and CVS Health to improve patient access to aducanumab, which received [...]
Mississippi Attorney General Sues Both Pharma and PBMs as Insulin Prices Soar
Mississippi has accused insulin manufacturers and pharmacy benefit managers (PBMs) of working together to maintain insulin prices unmanageably high. Mississippi [...]
White Paper Details Pharmacoeconomics Analysis Considerations
A new white paper, provided by Dr. Nina Lathia, details the critical elements of an effective pharmacoeconomics (PE) analysis. Dr. [...]
Senate Democrats Discuss Alternative Drug Pricing Bill; Pelosi’s Bill Could Lead to $500 Billion in Savings
Senate Democrats are considering a new proposal to reduce drug prices. New Jersey’s Senator Bob Menendez noted that despite efforts [...]
Johns Hopkins Researchers Discuss Burden of Ultra-Expensive Drugs on Medicare as Spending Increases 1,170%
Researchers at the Johns Hopkins Bloomberg School of Public Health published an article on a select category of medications: ultra-expensive [...]
CEVR Researchers Publish Article on Strengths of Value-Based Healthcare and HTAs
Leading researchers at Tufts University School of Medicine’s Center for the Evaluation of Value and Risk in Health (CEVR) have [...]
Survey Shows Americans Strongly Support Medicare Negotiation Amid Pharma’s Claims of Negative Impact to Innovation
A new survey shows that most Americans, both Democrats and Republicans, support negotiation by the federal government in prices of [...]
ICER Publishes Fairness Assessment Protocol in New Healthcare Equity Initiative
The Institute for Clinical and Economic Review (ICER) will begin considering barriers to drug access in an effort to promote [...]
AHIP Analysis Finds High Healthcare Spending on Prescription Drugs by Payers
America’s Health Insurance Plans (AHIP) has found that the largest proportion of payers’ healthcare spending goes to prescription drugs, upon [...]
FDA’s Accelerated Approval of Alzheimer’s Drug Faces Widespread Backlash and Scrutiny
Biogen’s aducanumab drug was approved earlier this week by the Food and Drug Administration (FDA). The drug is intended for [...]
Budget Oncology Drug Could Rival Top Lung Cancer Chemotherapies
A new drug created by Chinese CStone Pharmaceuticals and EQRx offers a low-cost alternative in the crowded lung cancer chemotherapy [...]
Endpoints News Seeks Your Thoughts on FDA’s Aducanumab Approval
Endpoints News has released a poll regarding the Food and Drug Administration’s approval of aducanumab for use in Alzheimer’s disease. [...]
Biogen’s Alzheimer’s Drug Could Face Efficacy Checkpoints Amid Pricing Concerns
Biogen’s FDA-approved Alzheimer’s drug, aducanumab, faces uncertainty amid efficacy and pricing concerns. Now, experts are pushing the Centers for Medicare [...]